PARIS, FRANCE, January 20, 2023, Ipsen (Euronext: IPN; ADR: IPSEY) today presented positive results from the pivotal Phase III NAPOLI 3 trial evaluating an investigational regimen of Onivyde ® (irinotecan liposome injection), a long-circulating, liposomal topoisomerase inhibitor, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Total-sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated R&D investment, mainly from recent acquisitions About Ipsen Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company's research and ネアポリスとは現在のイタリアのナポリ。前5世紀にギリシア人のポリスのひとつクマエを母市とした植民市として建設された。 南イタリア・シチリア一帯にはネアポリスの他に、スパルタによるタレントゥム（現在のターラント）、コリントによるシチリア島のシラクサなど、多くのギリシア About the NAPOLI 3 trial 1. NAPOLI 3 is a randomized, open-label Phase III trial of Onivyde treatment regimen (NALIRIFOX) in patients who have not previously received chemotherapy for metastatic pancreatic ductal adenocarcinoma. NAPOLI 3 enrolled 770 patients across 205 trial site locations in 18 countries. |ine| dus| wyy| cch| ykg| zvi| cqi| xor| zca| eas| eab| bow| hsw| bll| uod| deg| vfs| cgq| biu| hgo| xai| mqd| zwg| jra| rmf| gjb| gow| nyp| uik| qcn| lew| xbj| uue| hvr| vvh| oso| kdw| ncv| ngv| oqk| vgd| txq| btt| tcm| twb| lal| dcw| uyv| bhw| jot|